Pharma Pulse 7/25/24: CrowdStrike Explains What Went Wrong Days After Global Tech Outage, The Future of Biosimilars & more

The Future of Biosimilars

Biocon Biologic’s chief commercial officer of advanced markets discusses the current market and potential trends for biosimilars.

Oral Dissolvable Birth Control Pill Receives Approval From the FDA

The decision offers patients with difficulty swallowing their medication expanded options for treatment administration.

CrowdStrike Explains What Went Wrong Days After Global Tech Outage

Cybersecurity company lays out steps to prevent future quality-control disruptions.

Pfizer Announces Positive Topline Results From Phase III Study of Hemophilia A Gene Therapy Candidate

Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis.

@fda on Threads

Make a pledge today to prioritize our health. If you have questions about your medications, don't hesitate to reach out to us at the FDA.

We're here to help you take care of you!

Contact us:

✉️ [email protected]

📞 1-855-543-3784

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs